Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."

All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.

All patients received 20-40 mg oral or intravenous dexamethasone

All patients received venetoclax 400mg daily.